Polymorphisms of NRF2 and NRF2 target genes in urinary bladder cancer patients

Purpose NRF2 transcription factor is involved in modulation of various antioxidant and metabolic genes and, therefore, may modulate anti-carcinogenic potential. Association between polymorphisms of NRF2 and five NRF2-regulated genes and urinary bladder cancer (BC) risk was analyzed. Methods The stud...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of cancer research and clinical oncology 2014-10, Vol.140 (10), p.1723-1731
Hauptverfasser: Reszka, Edyta, Jablonowski, Zbigniew, Wieczorek, Edyta, Jablonska, Ewa, Krol, Magdalena Beata, Gromadzinska, Jolanta, Grzegorczyk, Adam, Sosnowski, Marek, Wasowicz, Wojciech
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Purpose NRF2 transcription factor is involved in modulation of various antioxidant and metabolic genes and, therefore, may modulate anti-carcinogenic potential. Association between polymorphisms of NRF2 and five NRF2-regulated genes and urinary bladder cancer (BC) risk was analyzed. Methods The study group included 244 BC patients, while the control group comprised 365 individuals with no evidence of malignancy. Genotyping of GSTM1 (deletion), GSTT1 (deletion), GSTA1 −69C/T (rs3957357), GSTP1 Ile105Val (rs1695), SOD2 Ala16Val (rs4880) and NRF2 −617C/A (rs6721961) in blood genomic DNA was performed by means of real-time PCR assays. The associations between gene polymorphism and BC risk were computed by logistic regression. Results The frequency of GSTA1, GSTP1, SOD2 and NRF2 genotypes did not differ in both groups. A significantly higher BC risk was associated with GSTM1 null genotype after adjusting to age, sex and smoking habit (OR 1.85, 95 % CI 1.30–2.62; P  = 0.001). GSTT1 null (OR 0.50, 95 % CI 0.31–0.81; P  = 0.005) and GSTP1 Val105Val (OR 0.52, 95 % CI 0.27–0.98; P  = 0.04) genotypes were associated with reduced BC risk separately or in combination (OR 0.24, 95 % CI 0.11–0.51; P  
ISSN:0171-5216
1432-1335
DOI:10.1007/s00432-014-1733-0